Market data
Medical Conditions Disorders
Explore verified medical conditions disorders statistics and market research reports with sourced data and trend analysis.
Latest update:
Elif Demirci
Orthorexia Statistics
Orthorexia has a measurable grip on everyday eating habits, with 2026 data showing a sharp jump in how often people feel compelled to follow strict food rules. These statistics also reveal a surprising flip where “healthy” goals start crowding out social life and flexibility, making it worth understanding the pattern before it becomes personal.
Gout Statistics
Gout leaves a huge footprint that goes far beyond painful flare ups with about 1.02 million deaths linked to gout globally in 2017 and U.S. adults 65 and older showing 26.3 percent prevalence in 2016 to 2017. You will also see how costs and care habits collide such as prophylaxis use during ULT start stuck at 40 percent while treat to target approaches can cut persistent hyperuricemia by 48 percent, alongside sobering figures on cardiovascular comorbidity and hospital and ED use soon after attacks.
United States Cancer Statistics
Cancer survival and burden numbers in the United States pull in opposite directions. A 20.9% five year relative survival rate for all cancers combined sits beside striking stage gaps like 90% for localized colorectal cancer and 3% for distant pancreatic cancer, plus the cost pressures totaling $156.6 billion in direct medical spending in 2022.
Eczema Statistics
Eczema is more than a seasonal flare, with millions living through relentless symptoms that can reshape sleep, work, and daily routines. Get the newest 2025 and 2026 statistics side by side with the spending and care gaps that explain why so many people still struggle to get relief.
Colon Cancer In 20S Statistics
Even with colon cancer still often treated as a concern for later decades, 2025 data suggests the risk in people in their 20s is not zero and the cases are rising in ways that can be easy to miss. This page turns those unsettling trends into clear, practical context so you can understand what is changing and why it matters right now.
Cerebral Palsy Statistics
Find out why cerebral palsy is more than a motor diagnosis, with 17.4% of children in the CPIR cohort carrying at least one comorbidity and 60% reporting musculoskeletal problems such as pain or contractures. From England’s birth prevalence of 2.0 per 1,000 to the cost impact and care gaps seen in claims and cohorts, this page connects what happens around birth to what families face long after.
Rabies Statistics
With rabies nearly always fatal once symptoms begin, the page connects the urgency of getting PEP to the scale behind it, including WHO’s estimate of 3.7 million PEP treatments each year and the dog bite reality driving transmission. It also contrasts rapidly changing regional patterns like Latin America’s shift toward bat transmitted rabies with US surveillance and market forecasts, showing how prevention targets, not just treatment access, shape outcomes and costs.
Aphantasia Statistics
By the 2025 numbers, aphantasia is no longer the rare curiosity many assume it to be, with prevalence figures sharp enough to change how we talk about minds that do not picture. You will also see what the same mental blind spot predicts in daily life and memory, turning “no visual imagination” into measurable, everyday patterns.
Diabetes Amputations Statistics
Diabetes Amputations statistics capture a startling mismatch between risk and reality, with the latest 2025 figures showing how often serious outcomes follow poorly controlled disease. If you have ever wondered how quickly complications escalate, these numbers make the timeline impossible to ignore.
Herpes Transmission Statistics
From 12.7% down to 6.8%, daily suppressive acyclovir in discordant HSV-1 couples shows transmission can nearly halve, while suppressive therapy also cuts shedding by about half even when lesions never appear. With US outpatient herpes visits up 9% from 2013 to 2018 and 11.3 million new HSV-2 infections worldwide in 2016, this page connects treatment, invisible shedding, and real world spread into one practical picture of what actually lowers risk.
Esophageal Cancer Statistics
Esophageal cancer remains one of the few cancers where the outlook is still tightly bound to late detection, and the most recent figures capture how quickly risk and survival diverge once symptoms are missed. Get the latest incidence and survival patterns behind the alarming survival gap, so you can understand what is changing now and what has not.
Ibs Statistics
IBS affects about 12.0% of U.S. adults, yet only 2.0% report having an IBS diagnosis in the 2020 NHIS, a gap that helps explain why the condition drives billions in U.S. costs and a heavy share of gastroenterology visits. This page connects prevalence with real world care patterns and treatment outcomes, from medication persistence and diet and CBT effects to what guidelines recommend when alarm features are absent.
Atherosclerosis Statistics
Atherosclerosis still fuels a staggering share of cardiovascular deaths, but the latest figures show how rapidly risk profiles are shifting and why prevention can’t wait. Get the current numbers on prevalence, trends, and who is most affected, so you can see where the gap between treatment and outcomes is widening or closing.
Pressure Ulcer Statistics
Pressure ulcers don’t wait for bad luck, the latest figures show up as a persistent risk during routine care, and they can spell preventable harm when prevention slips. This page pinpoints the most current pressure ulcer statistics and the sharp differences behind them, so you can see where effort most urgently needs to land.
Pancreatic Cancer Age Statistics
Most pancreatic cancer diagnoses cluster after age 65, with a U.S. median age at diagnosis of 71 years, and survival drops sharply with time and treatment access. This Pancreatic Cancer Age stats page connects that shift to real outcomes, including resection survival of 18.0 months for patients aged 75 and older versus 29.2 months for younger patients, plus how age drives lower chemotherapy use and higher mortality risks.
World Cancer Statistics
Cancer burden is shifting fast, with GLOBOCAN projecting a 28% rise in new cases and a 47% rise in deaths between 2020 and 2040, while Asia already accounts for 44% of cancer deaths. This World Cancer page brings together the latest incidence and mortality by country and cancer type plus the prevention and screening gaps that can turn those trajectories around, from tobacco and infections to HPV and lung cancer low-dose CT outcomes.
Genital Herpes Statistics
Genital herpes keeps changing in the numbers, and the latest 2025 figures show who is most affected now and how fast new cases are shifting. If you want to understand the real scale behind genital outbreaks, this page lays out the statistics in plain terms.
Cancer Diagnosis Statistics
With cancer deaths projected to reach 611,720 in 2024, the page maps how delays stack up from symptoms and abnormal screening results to actual treatment times across breast, colorectal, and lung cancer. It also connects access gaps and late-stage diagnosis with the rise of cutting-edge diagnostics, from FDA authorized liquid biopsy companion testing to accelerating global molecular, digital pathology, and AI markets.
Hermaphrodite Statistics
Hermaphrodite statistics reveal a sharp shift in how often people encounter intersex topics, with the newest figures showing real changes rather than slow drift. Get the context behind the headline numbers and see what those trends mean for healthcare, visibility, and everyday understanding right now.
Autoimmune Disease Statistics
From 5% of U.S. adults living with Sjögren’s syndrome and lupus affecting about 2%, to rheumatoid arthritis tied to 4.6% of total U.S. health expenditures, these autoimmune disease statistics put a price and a prevalence tag on what so often stays invisible. You will also see why delays to diagnosis run years and how that turns into billions in annual costs and accelerating market growth, including $28.0 billion in expected global autoimmune therapeutics spending.